Molecular Templates, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- Document and Entity Information
Financial Statements
Notes to Financial Statements
Accounting Policies
- Organization and Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Collaboration Arrangements - Additional Information (Detail)

v3.3.0.814

Collaboration Arrangements - Additional Information (Detail) - Merck KGaA - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront and milestone payments received to date			$ 110,000,000
Revenue recognized by the Company	$ 3,700,000	$ 3,700,000	11,000,000	$ 11,000,000
Company received a reimbursement for eligible worldwide development expenses	$ 3,800,000	$ 4,800,000	$ 9,500,000	$ 14,200,000
United States
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Portion of profits that Company is eligible to participate, depending upon total sales			50.00%
Regulatory and Development Milestones \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential future milestones			$ 100,000,000
Commercialization Milestones \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential future milestones			$ 340,000,000
Collaborative Arrangement Product Agreement \| Evofosfamide
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Merck KGaA's percentage share of worldwide development expenses			70.00%

- Definition

Portion of profits that Company is eligible to participate, depending upon total sales.

+ References

No definition available.

+ Details

Name:	thld_PortionOfProfitsDependingOnSales
Namespace Prefix:	thld_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential future milestone payments.

+ References

No definition available.

+ Details

Name:	thld_PotentialMilestonePayments
Namespace Prefix:	thld_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Merck KGaA's percentage share of worldwide development expenses.

+ References

No definition available.

+ Details

Name:	thld_WorldwideDevelopmentExpensesSharePercentage
Namespace Prefix:	thld_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Return of or reimbursements received in relation to direct costs and expenses previously paid or incurred.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_RecoveryOfDirectCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=thld_MerckKGaAMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=thld_RegulatoryAndDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=thld_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=thld_EvofosfamideMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: